This is a Phase II clinical trial aimed at treating patients with T-cell lymphomas (T-cell blood cancers). The drug consists of a toxin, called diphtheria toxin, which is attached to an antibody that can specifically target cancerous T-cells. Our primary objectives are, therefore, to determine the patient subgroup with respect to disease burden who best responds to this experimental drug in treating CD3 positive T cell malignancies. We will be determining how the patient and their disease respond to this research agent.
For more information: http://clinicaltrials.gov/ct2/show/study/NCT00611208?view=record
Travel & Lodging Defrayment
As a result of study participation, travel will be requested to a participating medical center. Angimmune (the study sponsor) will partially pay to defray travel & lodging costs for a family member to accompany a patient to this trial. Please contact the appropriate Clinical Research Coordinator at the trial site listed below for more information.
University of Texas MD Anderson Cancer Center - Recruiting
Houston, Texas, United States, 77030
Contact: Carol Wilson, RN 713-563-4655 email@example.com
Contact: Vicki Jeanis, RN 713-745-0367 firstname.lastname@example.org
Principal Investigator: Madeleine Duvic, MD
Sub-Investigator: Susan O'Brien, MD
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.